Experimental pharmacology of hirunorm: a novel synthetic peptide thrombin inhibitor.

Functional evidence for the ability of angiotensin AT1 receptor antagonists to cross the blood-brain barrier in rats.

Cyclosporin H is a potent and selective competitive antagonist of human basophil activation by N-formyl-methionyl-leucyl-phenylalanine.

Definition of cut-off points for autoantibody assays in cohorts of healthy individuals. The Sardinian School Children-IDDM (SSI) & Newborn-IDDM (SNI) Study Groups.

N-3-substituted pyrimidinones as potent, orally active, AT1 selective angiotensin II receptor antagonists.

Prothrombin fragment F 1+2 levels are high in NIDDM patients independently of the Hb A1 c.

4-Diazinyl- and 4-pyridinylimidazoles: potent angiotensin II antagonists. A study of their activity and computational characterization.

The selective angiotensin AT1 receptor antagonist LR-B/081 potently inhibits drinking induced by central injection of angiotensin II in rats.

Pharmacology of LR-B/057, a novel orally active AT1 receptor antagonist.

Pharmacology of LR-B/081, a new highly potent, selective and orally active, nonpeptide angiotensin II AT1 receptor antagonist.

[Pneumatosis cystoides intestinalis in a patient treated with an allogeneic bone marrow transplant. A case report].

[Low levels of dehydroepiandrosterone sulfate in adult males with insulin-dependent diabetes mellitus].

Endothelium as a therapeutical target in peripheral occlusive arterial diseases: consideration for pharmacological interventions.

Beneficial effects of cloricromene in ischemic reperfused myocardium.

Dissociation of the anti-ischaemic effects of cloricromene from its anti-platelet activity.